The BSRBR-RA study tracks the progress of people with rheumatoid arthritis (RA) who have been prescribed biologic (including biosimilar) and other targeted therapies in the UK to monitor the long-term safety of these drugs.
To find out more about the study, please visit our main site.
Latest blog posts
Join Us at the BSR Rheumatology Conference 24-26 April 2024!
We are thrilled to extend a warm invitation to join our sessions at the BSR’s Rheumatology conference. Held between 24th – 26th April 2024 at the ACC in Liverpool, this conference promises a wide variety of talks across all aspects of rheumatology and rheumatology...
Tyenne (tocilizumab) – the new biosimilar on the block
What is Tyenne? Tyenne is the first tocilizumab (interleukin-6) biosimilar that has recently been approved by the European Medicines Agency (EMA) for the treatment of moderate to severe rheumatoid arthritis in adults. It is now starting to be prescribed in the UK and...
Welcome to our new blog for the BSRBR-RA study!
What is the BSRBR-RA?BSRBR-RA is the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. The primary aim of the study is to monitor the long term safety of biologics, biosimilars and other targeted therapies. Originally set up in 2001, the...
NIHR Associate Principal Investigator Scheme
The BSRBR-RA Study (UK CRN ID: 7302) has joined the NIHR Associate Principal Investigator Scheme. The Associate Principal Investigator (PI) Scheme is a six month in-work training opportunity, providing practical experience for healthcare professionals starting their...
Switching from the original etanercept (the originator) to an etanercept biosimilar for rheumatoid arthritis (RA) – patients do just as well as those who remained on the originator.
Researchers: Lianne Kearsley-Fleet, Aasiyah Rokad, Man-Fung Tsoi, Sizheng Steven Zhao, Mark Lunt, Kath D. Watson, BSRBR-RA Contributors Group, Kimme L. Hyrich. What was already known? Etanercept is one of the main treatment options for patients with rheumatoid...
BSRBR-RA featured on Talking Rheumatology Spotlight podcast!
Prof Kimme Hyrich and Dr Kath Watson from the BSRBR-RA talk to Dr Roz Benson about all things registry, including why the registry was set up, the volume of data (it's big!), publications, high impact papers and ways to get involved. Related ...
Contact Us
+44 (0) 161 306 6000
Recent Comments